替吉奥与氟尿嘧啶治疗中晚期消化道肿瘤疗效的系统评价
付红1
作者信息
- 1. 辽宁省岫岩县中心人民医院内三科，辽宁 岫岩 114300
- 折叠
摘要
目的：对国内外有关替吉奥和氟尿嘧啶治疗中晚期消化道肿瘤的临床资料进行系统评价，探讨两者临床价值。方法通过检索国内外各类数据库，利用软件包进行数据整合分析，并对测量指标进行评估。结果替吉奥可提高患者两年总生存率，但无法提高其他时间总生存率；在对中性粒细胞影响方面，替吉奥比氟尿嘧啶小，且对血液内钾、镁、磷等含量影响不大，但对胆红素会产生较大影响。结论替吉奥无法延长中晚期消化道恶性肿瘤患者总生存期，相对于氟尿嘧啶来说，替吉奥可以降低药物对患者身体的影响，同时还能减缓部分消化道症状，但会对胆红素造成较大影响。
Abstract
Objective To evaluate the randomized trials of S -1 or fluorouracil for the treatment of middle -late digestive system neoplasms systematically .Method Use the software package to analysis the data from all kinds of domestic and foreign database and evaluate the measurements .Results S-1 can improve the overall surviv-al up to 24 hours,but fail to improve the overall survival.The effect of S-1 over neutrophils was less than that of flurouracil.Conclusion S-1 cannot prolong the overall survival in patients with middle-late digestive system neoplasms.Compared with fluorouracil,S-1 can reduce the effects of the drugs over patients’body,and at the same time,it can also retard the digestive tract symptoms,but it will cause great influence on bilirubin.
关键词
替吉奥/氟尿嘧啶/中晚期消化道肿瘤/疗效评价Key words
S-1/Fluorouracil/Middle-late Digestive system neoplasms/Curative effect evaluation引用本文复制引用
出版年
2014
NETL
NSTL
万方数据